Advertisement

Schizophrenia and Related Psychoses

  • Selma Bozkurt Zincir
Chapter

Abstract

Pregnancy and postpartum period (perinatal period) are not protective in terms of schizophrenia; contrarily perinatal period may lead to an exacerbation of symptoms of a patient in remission. Cessation of existing treatment or attempt to replace a currently effective antipsychotic drug during pregnancy increases exacerbation risk even more. Patients who stopped their antipsychotic drug treatment have two- to threefold increased possible recurrence risk compared to continuation of treatment and in sudden drug withdrawals have increased risk of recurrence compared to gradual withdrawals. According to our current knowledge, psychotic relapse ratio of patients with schizophrenia is higher during early postpartum period (mostly seen at the first 3 months after birth) rather than pregnancy. Acute psychotic exacerbation of schizophrenia related to leaving the pharmacological treatment or stress factors at the postpartum period has a risk of harm to the baby. Choosing an antipsychotic drug for the treatment of a woman diagnosed with schizophrenia during perinatal period requires a holistic approach in order to maximize both the maternal and child’s physical and mental well-being. Each treatment option should therefore be thoroughly discussed, and the decision should be based on balancing the benefits and risks, with considerations for patient preference and other patient factors.

Keywords

Schizophrenia Perinatal period Pregnancy Postpartum period Pharmacological treatment Antipsychotics 

References

  1. 1.
    Öztürk O. Ruh Sağlığı ve Bozuklukları, 13th ed., Ankara; 2015. pp. 42–8 (In Turkish).Google Scholar
  2. 2.
    Bozkurt Zincir S. Gebelik Döneminde Şizofreni. In: Uguz F, editor. Gebelik ve Postpartum Dönemde Psikiyatrik Bozukluklar. Istanbul: İstanbul Medikal Yayıncılık; 2017. p. 49–65. in Turkish.Google Scholar
  3. 3.
    Vigod SN, Kurdyak PA, Dennis CL, Gruneir A, Newman A, Seeman MV. Maternal and newborn outcomes among women with schizophrenia: a retrospective population based cohort study. BJOG. 2014;121:566–74.PubMedGoogle Scholar
  4. 4.
    Howard LM. Fertility and pregnancy in women with psychotic disorders. Eur J Obstet Gynaecol Reprod Biol. 2005;119:3–10.CrossRefGoogle Scholar
  5. 5.
    Laursen TM, Olsen TM. Reproductive patterns in psychotic patients. Schizophr Res. 2010;121:234–40.CrossRefGoogle Scholar
  6. 6.
    Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, Hammad TA, Li DK, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffenreffer K, Avalos LA, Andrade SE. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001–2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health. 2013;16:149–57.CrossRefGoogle Scholar
  7. 7.
    Rahmati M, Rahgozar M, Fadaei F, Bakhshi E, Cheraghi L. Identifying some risk factors of time to relapses in schizophrenic patients using bayesian approach with event-dependent frailty model. Iran J Psychiatry. 2015;10(2):123–7.Google Scholar
  8. 8.
    Özdamar Ö, Yılmaz O, Beyca HH, Muhcu M. Gebelik ve postpartum dönemde sık görülen ruhsal bozukluklar. Zeynep Kamil Tıp Bülteni. 2014;45:71–7. In TurkishCrossRefGoogle Scholar
  9. 9.
    Robinson GE. Treatment of schizophrenia in pregnancy and postpartum. J Popul Ther Clin Pharmacol. 2012;19:380–6.Google Scholar
  10. 10.
    Barnes TRE, The Schizophrenia Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567–620.CrossRefGoogle Scholar
  11. 11.
    Matevosyan NR. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. Arch Gynecol Obstet. 2011;283:141–7.CrossRefGoogle Scholar
  12. 12.
    Solari H, Dickson KE, Miller L. Understanding and treating women with schizophrenia during pregnancy and postpartum. Can J Clin Pharmacol. 2009;16:e23–32.PubMedGoogle Scholar
  13. 13.
    Howard LM, Kumar C, Leese M, Thornicroft G. The general fertility rate in women with psychotic disorders. Am J Psychiatry. 2002;159:991–7.CrossRefGoogle Scholar
  14. 14.
    Bülbül F, Çöpoglu ÜS, Demir B, Bulut M, Alpak G, Ünal A, Savaş H. Psikiyatrik hastalığı nedeniyle yatarak tedavi gören gebe hastaların klinik ve sosyodemografik özellikleri ve izlem sonuçları. Düşünen Adam. J Psychiatry Neurol Sci. 2014;27:21–6. in TurkishGoogle Scholar
  15. 15.
    Miller LJ. Sexuality, reproduction, and family planning in women with schizophrenia. Schizophr Bull. 1997;23:623–35.CrossRefGoogle Scholar
  16. 16.
    Bennedsen BE, Mortensen PB, Olesen A, Henriksen TB. Congenital malformations, stillbirths and infant deaths among children of women with schizophrenia. Arch Gen Psychiatry. 2001;58:674–9.CrossRefGoogle Scholar
  17. 17.
    Jablensky VA, Morgan V, Zubrick SR, Bower C, Yellachich L. Pregnancy, delivery and neonatal complications in population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162:79–91.CrossRefGoogle Scholar
  18. 18.
    Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hultman CM. Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res. 2002;58:221–9.CrossRefGoogle Scholar
  19. 19.
    Nilsson E, Hultman CM, Cnattingius S, Olausson PO, Björk C, Lichtenstein P. Schizophrenia and offspring’s risk for adverse pregnancy outcomes and infant death. Br J Psychiatry. 2008;193:311–5.CrossRefGoogle Scholar
  20. 20.
    King-Hele S, Webb RT, Mortensen PB, Appleby L, Pickles A, Abel KM. Risk of stillbirth and neonatal death linked with maternal mental illness: a national cohort study. Arch Dis Childhood Fet Neonat Ed. 2009;94:105–10.CrossRefGoogle Scholar
  21. 21.
    King-Hele SA, Abel KM, Webb RT, Mortensen PB, Appleby L, Pickles AR. Risk of sudden infant death syndrome with parental mental illness. Arch Gen Psychiatry. 2007;64:1323–30.CrossRefGoogle Scholar
  22. 22.
    Hoirisch-Clapauch S, Brenner B, Nardi AE. Adverse obstetric and neonatal outcomes in women with mental disorders. Thromb Res. 2015;135(Suppl 1):S60–3.CrossRefGoogle Scholar
  23. 23.
    Nosarti C, Froudist-Walsh S. Alterations in development of hippocampal and cortical memory mechanisms following very preterm birth. Dev Med Child Neurol. 2016;58:35–45.CrossRefGoogle Scholar
  24. 24.
    Webb R, Abel K, Pickles A, Appleby L. Mortality of offspring of parents with psychotic disorders: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1045–56.CrossRefGoogle Scholar
  25. 25.
    Hizkiyahu R, Levy A, Sheiner E. Pregnancy outcome of patients with schizophrenia. Am J Perinatol. 2010;27:19–23.CrossRefGoogle Scholar
  26. 26.
    Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28:279–88.CrossRefGoogle Scholar
  27. 27.
    Seeman MV. Clinical interventions for women with schizophrenia: pregnancy. Acta Psychiatr Scand. 2013;127:12–22.CrossRefGoogle Scholar
  28. 28.
    Einarson A. Antipsychotic medication (safety/risk) during pregnancy and breastfeeding. Curr Women’s Health Rev. 2010;6:34–8.CrossRefGoogle Scholar
  29. 29.
    Dodd S, Berk M. The Safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium. Curr Drug Saf. 2006;1:25–33.CrossRefGoogle Scholar
  30. 30.
    Poo SXW, Agius M. Atypical antipsychotics for schizophrenia and/or bipolar disorder in pregnancy: current recommendations and updates in the NICE guidelines. Psychiatr Danub. 2015;27.(Suppl. 1:255–60.Google Scholar
  31. 31.
    National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance (NICE CG192). London: National Institute for Health and Care Excellence; 2015.Google Scholar
  32. 32.
    Jayashri K, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R. Antipsychotic use in pregnancy. Expert Opin Pharmacother. 2015;16:1335–45.Google Scholar
  33. 33.
    McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66:444–9.CrossRefGoogle Scholar
  34. 34.
    Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69:715–21.CrossRefGoogle Scholar
  35. 35.
    Kulkarni J, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R. Antipsychotic use in pregnancy. Expert Opin Pharmacother. 2015;16:1335–45.CrossRefGoogle Scholar
  36. 36.
    Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;363:518–44.CrossRefGoogle Scholar
  37. 37.
    Robakis T, Williams KE. Atypical antipsychotics during pregnancy. Curr Psychiatry. 2013;12:12–8.Google Scholar
  38. 38.
    Bozkurt Zincir S. Perinatal Dönemde Antipsikotik İlaçlar. In: Uguz F, editor. Gebelik ve Postpartum Dönemde Psikiyatrik Bozukluklar. Istanbul: İstanbul Medikal Yayıncılık; 2017. p. 227–57.Google Scholar
  39. 39.
    Tomruk NB, Saatçioğlu Ö. Treatment challenges in schizophrenia in perinatal period and infanticide. Bull Clin Psychopharmacol. 2010;20:266–8.CrossRefGoogle Scholar
  40. 40.
    Doucet S, Jones I, Letourneau N, Dennis CL, Blackmore ER. Interventions for the prevention and treatment of postpartum psychosis: a systematic review. Arch Womens Ment Health. 2011;14:89–98.CrossRefGoogle Scholar
  41. 41.
    Uguz F. Second generation antipsychotics during the lactation period: a comparative systematic review on infant safety. J Clin Psychopharmacol. 2016;36:244–52.CrossRefGoogle Scholar
  42. 42.
    Spinelli MG. Postpartum psychosis: detection of risk and management. Am J Psychiatry. 2009;166:405–8.CrossRefGoogle Scholar
  43. 43.
    Babu GN, Desai G, Chandra PS. Antipsychotics in pregnancy and lactation. Indian J Psychiatry. 2015;57(2):303–7.CrossRefGoogle Scholar
  44. 44.
    Gentile S. Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry. 2008;69:666–73.CrossRefGoogle Scholar
  45. 45.
    Klinger G, Stahl B, Fusar-Poli P, Merlob P. Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev. 2013;10:308–17.PubMedGoogle Scholar
  46. 46.
    Sharma V. Treatment of postpartum psychosis: challenges and opportunities. Curr Drug Saf. 2008;3:76–81.CrossRefGoogle Scholar
  47. 47.
    Niemi L, Suvisaari J, Haukka J, Wrede G, Lonnqvist J. Cumulative incidence of mental disorders among offspring of mothers with psychotic disorder. Results from the Helsinki high-risk study. Br J Psychiatry. 2004;185:11–7.CrossRefGoogle Scholar
  48. 48.
    Snellen M, Mack K, Trauer T. Schizophrenia, mental state, and mother-infant interaction: examining the relationship. Aust N Z J Psychiatry. 1999;33:902–11.CrossRefGoogle Scholar
  49. 49.
    Aydin B, Nayir T, Sahin S, Yıldız A. Olanzapine and quetiapine use during breastfeeding: excretion into breast milk and safe breastfeeding strategy. J Clin Psychopharmacol. 2015;35:206–8.CrossRefGoogle Scholar
  50. 50.
    Mendhekar DN. Possible delayed speech acquisition with clozapine therapy during pregnancy and lactation. J Neuropsychiatry Clin Neurosci. 2007;19:196–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Selma Bozkurt Zincir
    • 1
  1. 1.Department of Psychiatry, Faculty of Medicine, Göztepe Medicalpark Training HospitalBahçeşehir UniversityIstanbulTurkey

Personalised recommendations